TY - JOUR
T1 - Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma)
T2 - A single-center experience
AU - D'Souza, Anita
AU - Lacy, Martha
AU - Gertz, Morie
AU - Kumar, Shaji
AU - Buadi, Francis
AU - Hayman, Suzanne
AU - Dingli, David
AU - Zeldenrust, Steven
AU - Kyle, Robert
AU - Ansell, Stephen
AU - Inwards, David
AU - Johnston, Patrick
AU - Micallef, Ivana
AU - Porrata, Luis
AU - Litzow, Mark
AU - Gastineau, Dennis
AU - Hogan, William
AU - Dispenzieri, Angela
PY - 2012/7/5
Y1 - 2012/7/5
N2 - The POEMS syndrome (polyradiculoneuropathy, organomegaly, multiple endocrinopathies, monoclonal protein, skin changes) is a rare disease associated with a plasma cell dyscrasia. Patients with disseminated POEMS can be treated with high-dose therapy and autologous stem cell transplantation (ASCT). While clinical improvement is nearly universal in these patients, the long-term outcomes after transplantation are unclear.We therefore assessed the long-term clinical outcomes of 59 POEMS patients treated with ASCT at our institution. With a median follow-up of 45 months, 14 patients have progressed with a progression-free survival of 98% and 75% at 1 and 5 years, respectively. Factors associated with progression have included an IgG-λ monoclonal component (hazard ratio [HR] 7.5; 95% confidence interval [CI], 2.3-28.3; P = .0008), fluorodeoxyglucose-avid lesions on baseline positron emission tomography (HR 6.4; 95% CI, 1.2-120; P = .03), lack of complete hematologic response (HR 5.4; 95% CI, 1.8-16.7; P = .003), and patients aged 50 years or younger at transplantation (HR 4.4; 95% CI, 1.3-20; P = .01). The most common progression events have been radiologic followed by rising VEGF. Symptomatic progression has been rare. Most patients could be salvaged with immunomodulatory drugs or radiation. The 5-year survival is 94%. Herein, we describe a system of monitoring response and progression among patients with POEMS after ASCT.
AB - The POEMS syndrome (polyradiculoneuropathy, organomegaly, multiple endocrinopathies, monoclonal protein, skin changes) is a rare disease associated with a plasma cell dyscrasia. Patients with disseminated POEMS can be treated with high-dose therapy and autologous stem cell transplantation (ASCT). While clinical improvement is nearly universal in these patients, the long-term outcomes after transplantation are unclear.We therefore assessed the long-term clinical outcomes of 59 POEMS patients treated with ASCT at our institution. With a median follow-up of 45 months, 14 patients have progressed with a progression-free survival of 98% and 75% at 1 and 5 years, respectively. Factors associated with progression have included an IgG-λ monoclonal component (hazard ratio [HR] 7.5; 95% confidence interval [CI], 2.3-28.3; P = .0008), fluorodeoxyglucose-avid lesions on baseline positron emission tomography (HR 6.4; 95% CI, 1.2-120; P = .03), lack of complete hematologic response (HR 5.4; 95% CI, 1.8-16.7; P = .003), and patients aged 50 years or younger at transplantation (HR 4.4; 95% CI, 1.3-20; P = .01). The most common progression events have been radiologic followed by rising VEGF. Symptomatic progression has been rare. Most patients could be salvaged with immunomodulatory drugs or radiation. The 5-year survival is 94%. Herein, we describe a system of monitoring response and progression among patients with POEMS after ASCT.
UR - http://www.scopus.com/inward/record.url?scp=84863569610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863569610&partnerID=8YFLogxK
U2 - 10.1182/blood-2012-04-423178
DO - 10.1182/blood-2012-04-423178
M3 - Article
C2 - 22611150
AN - SCOPUS:84863569610
SN - 0006-4971
VL - 120
SP - 56
EP - 62
JO - Blood
JF - Blood
IS - 1
ER -